EMEA-002304-PIP01-17 - paediatric investigation plan

andecaliximab

Key facts

• Active substance:
  andecaliximab
• Therapeutic area:
  Oncology
• Decision number:
  P/0169/2018
• PIP number:
  EMEA-002304-PIP01-17
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  15/06/2018
• Compliance check done:
  No

Decision

P/0169/2018: EMA decision of 15 June 2018 on the granting of a product specific waiver for andecaliximab (EMEA-002304-PIP01-17)

Adopted Reference Number: EMA/381994/2018